Skip to main content
SpringerLink
Log in

Dravet syndrome: high cost and QOL burden in Germany

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Zogenix International Ltd.

Reference

  • Strzelczyk A, et al. A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia : 27 Jun 2019. Available from: URL: http://doi.org/10.1111/epi.16099

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dravet syndrome: high cost and QOL burden in Germany. PharmacoEcon Outcomes News 832, 10 (2019). https://doi.org/10.1007/s40274-019-6036-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6036-x

Search

Navigation